Increasing prevalence of infectious disease is predominantly augmenting the growth of the recombinant vaccines market

 

Recombinant vaccines are made by expressing live viruses as proteins and then creating DNA sequences out of these viruses. The proteins, or nucleic acid strands, of the virus, have been repaired with a polymerase that creates a piece of DNA identical to the rest of the viruses'. These DNA fragments, or polymers, are injected into the body of a susceptible individual, usually in a vein or in a garage, through the vein wall. This protects the patient against the deadly infection caused by the virus. Most commonly used vaccines require one dose of a product and one dose of a vaccine mixture. This is called a single dose schedule.

The high prevalence of infectious diseases around the globe is driving the recombinant vaccines market growth. According to the World Health Organization, infectious diseases kill over 17 million people a year. An increasing number of the manufacturer in the recombinant vaccines market is again propelling the growth of the market. Moreover, advancement in the development of technologies used in the production of vaccines is further anticipated to foster the growth of the recombinant vaccines market. Furthermore, continuous investment in research & development for the production of new vaccines are projected to fuel the growth of recombinant vaccines.

North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of the infectious disease in the region. According to the National Center for Health Statistics, there were around new tuberculosis cases: 9,105, new salmonella cases: 54,285, new Lyme disease cases: 42,743, and new meningococcal disease cases: 353 in 2017.

Key Developments:

1.      In June 2020, Johnson & Johnson announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.

2.      In November 2020, The European Commission has granted marketing authorization for Supemtek®, a quadrivalent (four-strain) recombinant influenza vaccine, for the prevention of influenza in adults aged 18 years and older. Supemtek is the first and only recombinant influenza vaccine now approved in the European Union.

3.      In February 2020, scientists from Hong Kong and Macao special administrative regions announced a breakthrough in developing a recombinant COVID-19 vaccine indicating that the mass production of the vaccine is feasible at a low cost in the future.